These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28094444)

  • 21. A Novel Continuous Assay for the Deacylase Sirtuin 5 and Other Deacetylases.
    Roessler C; Tüting C; Meleshin M; Steegborn C; Schutkowski M
    J Med Chem; 2015 Sep; 58(18):7217-23. PubMed ID: 26308971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New chemical tools for probing activity and inhibition of the NAD
    Swyter S; Schiedel M; Monaldi D; Szunyogh S; Lehotzky A; Rumpf T; Ovádi J; Sippl W; Jung M
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer agents targeted to sirtuins.
    Kozako T; Suzuki T; Yoshimitsu M; Arima N; Honda S; Soeda S
    Molecules; 2014 Dec; 19(12):20295-313. PubMed ID: 25486244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition.
    Schnekenburger M; Mathieu V; Lefranc F; Jang JY; Masi M; Kijjoa A; Evidente A; Kim HJ; Kiss R; Dicato M; Han BW; Diederich M
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29401749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High glucose-induced oxidative stress represses sirtuin deacetylase expression and increases histone acetylation leading to neural tube defects.
    Yu J; Wu Y; Yang P
    J Neurochem; 2016 May; 137(3):371-83. PubMed ID: 26896748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirtuin 1 (SIRT1): the misunderstood HDAC.
    Stünkel W; Campbell RM
    J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors that target tubulin.
    Schemies J; Sippl W; Jung M
    Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirtuins (histone deacetylases III) in the cellular response to DNA damage--facts and hypotheses.
    Kruszewski M; Szumiel I
    DNA Repair (Amst); 2005 Nov; 4(11):1306-13. PubMed ID: 16084131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of activators and inhibitors of sirtuins.
    Balcerczyk A; Pirola L
    Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications.
    Cen Y; Youn DY; Sauve AA
    Curr Med Chem; 2011; 18(13):1919-35. PubMed ID: 21517779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cloning, chromosomal characterization and FISH mapping of the NAD(+)-dependent histone deacetylase gene sirtuin 5 in the mouse.
    Voelter-Mahlknecht S; Mahlknecht U
    Int J Oncol; 2013 Jul; 43(1):237-45. PubMed ID: 23673559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are sirtuin deacylase enzymes important modulators of mitochondrial energy metabolism?
    Osborne B; Cooney GJ; Turner N
    Biochim Biophys Acta; 2014 Apr; 1840(4):1295-302. PubMed ID: 23994496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New assays and approaches for discovery and design of Sirtuin modulators.
    Schutkowski M; Fischer F; Roessler C; Steegborn C
    Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirtuin activators and inhibitors: Promises, achievements, and challenges.
    Dai H; Sinclair DA; Ellis JL; Steegborn C
    Pharmacol Ther; 2018 Aug; 188():140-154. PubMed ID: 29577959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant Preparation, Biochemical Analysis, and Structure Determination of Sirtuin Family Histone/Protein Deacylases.
    Suenkel B; Steegborn C
    Methods Enzymol; 2016; 573():183-208. PubMed ID: 27372754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting aberrant cancer metabolism - The role of sirtuins.
    Kleszcz R; Paluszczak J; Baer-Dubowska W
    Pharmacol Rep; 2015 Dec; 67(6):1068-80. PubMed ID: 26481524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirtuins: the future insight.
    Suvarna BS
    Kathmandu Univ Med J (KUMJ); 2012; 10(38):77-82. PubMed ID: 23132482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docking and binding free energy calculations of sirtuin inhibitors.
    Karaman B; Sippl W
    Eur J Med Chem; 2015 Mar; 93():584-98. PubMed ID: 25748123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
    Kumar A; Chauhan S
    Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule regulation of Sir2 protein deacetylases.
    Grubisha O; Smith BC; Denu JM
    FEBS J; 2005 Sep; 272(18):4607-16. PubMed ID: 16156783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.